Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital

TipRanks

Sat, Jan 11, 2025, 8:20 AM 1 min read

BMO Capital lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $70 and keeps an Outperform rating on the shares. The company’s AATD discontinuation is the right decision and alleviates Intellia’s financing overhang, but the firm expects investors to question the timing of that decision with Phase 1 trial having just started, the analyst tells investors in a research note. The firm also continues to see Intellia shares as undervalued but warns that this week’s news may pressure the stock, BMO adds.

Stay Ahead of the Market:

Discover outperforming stocks and invest smarter with Top Smart Score Stocks
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on NTLA: